U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545590) titled 'A Study of Eltrekibart (LY3041658) in Healthy Participants' on April 16.
Brief Summary: The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants.
The study will last about 17 weeks.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: LY3041658
Administered SC
DRUG: LY3041658
Administered IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Curated by HT Syndication....